Clinical Trials Browser

Phase 2 × Not yet recruiting × venetoclax × Clear all

NCT05554419 2026-03-19

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07437950 2026-03-19

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06954987 2026-03-18

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07024706 2026-01-21

MAVRiC

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06470841 2024-08-22

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05628623 2024-07-03

ERASE

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06324994 2024-03-22

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Phase 2 Not yet recruiting

Lymphoma, Mantle-Cell